Cargando…
Tolerability of Alternative Dosing Schedules for Sunitinib: A Systematic Review and Meta-Analysis
PURPOSE: The standard schedule for sunitinib treatment is 4 weeks on and 2 weeks off (4/2) in first-line treatment for metastatic renal cell carcinoma (mRCC). Schedule modifications, including 2 weeks on and 1 week off (2/1), appear to reduce the total number of treatment-related adverse events (TRA...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Yonsei University College of Medicine
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515783/ https://www.ncbi.nlm.nih.gov/pubmed/32975057 http://dx.doi.org/10.3349/ymj.2020.61.10.837 |